BioCardia, Inc. Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
BioCardia, Inc. is a clinical-stage biotechnology company focused on regenerative therapies for cardiovascular disease. It is based in Sunnyvale, California, and is developing proprietary therapeutic programs for heart conditions, including CardiAMP and CardiALLO. These programs aim to address large unmet medical needs by delivering marrow-derived cells directly into the heart muscle, supported by the company's delivery platforms. Operating in the cellular and cell-derived therapeutics area, BioCardia targets clinicians and healthcare providers seeking regenerative options for cardiovascular patients. A notable development in March 2026 was the launch of its Helix transendocardial delivery catheter, accompanied by news that the FDA had accepted its pre-submission package.